Loading…
Biodexa Pharmaceuticals Plc is projected to rise to $2.84 by 2027, a +14% move from its current price of $2.49. BDRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.38 | $2.49 | $2.61 | +0.06% |
| Jul 13 | $2.34 | $2.49 | $2.66 | +0.13% |
| Jul 14 | $2.31 | $2.49 | $2.69 | +0.19% |
| Jul 15 | $2.28 | $2.50 | $2.73 | +0.26% |
| Jul 16 | $2.26 | $2.50 | $2.76 | +0.32% |
| Jul 17 | $2.24 | $2.50 | $2.79 | +0.39% |
| Jul 18 | $2.22 | $2.50 | $2.81 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.22 | $2.50 | $2.81 | +0.45% |
| Week 2 | $2.13 | $2.51 | $2.97 | +0.90% |
| Week 3 | $2.06 | $2.52 | $3.10 | +1.36% |
| Week 4 | $2.00 | $2.54 | $3.21 | +1.81% |
| Week 5 | $1.96 | $2.55 | $3.31 | +2.27% |
| Week 6 | $1.92 | $2.56 | $3.41 | +2.73% |
| Week 7 | $1.88 | $2.57 | $3.51 | +3.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biodexa Pharmaceuticals Plc is a healthcare company described as a clinical stage biopharmaceutical company focusing on a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company also develops MTX110, currently in Phase I studies for recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors.
In addition, Biodexa offers drug delivery platforms such as Q-Sphera, MidaSolve, and MidaCore, and has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
These facts establish Biodexa as a specialized healthcare company with a pipeline across multiple cancer types and metabolic disease, including products at various clinical stages and a portfolio of delivery technologies. The described collaborations and corporate history place it within the biopharma sector with a global research and development focus and a base in the United Kingdom.
BDRX is the trading symbol for Biodexa Pharmaceuticals Plc. The current price is $2.49 with a market capitalization of $2.25M, and the stock is ranked 5407 by market cap.
The outlook, based on the provided forecast, shows a path with varying annual averages and potential upside later in the horizon. The 2026 average price is $2.49, and powerfully later years show higher averages such as $5.60 by 2050, with corresponding max values reaching $12.79. These figures illustrate a long-run upward potential but reflect substantial variability across years.
Overall, the price trajectory is described through year-by-year forecasts with mixed sentiment up to 2031 and bullish momentum emerging in later years, underscoring the high uncertainty and the potential for both downside risk and future upside. As always, these are estimates, not guarantees, and actual results may differ.
A major floor 29.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 44.2% above — a clean break opens room to run.
A major ceiling 95.2% above — clearing it would confirm fresh momentum.
Key BDRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BDRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.65 | Sell | $2.63 | Sell |
| MA 10 | $2.78 | Sell | $2.72 | Sell |
| MA 20 | $2.84 | Sell | $2.85 | Sell |
| MA 50 | $3.22 | Sell | $3.31 | Sell |
| MA 100 | $3.69 | Sell | $6.04 | Sell |
| MA 200 | $13.37 | Sell | $240.85 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.07 | Neutral |
| Stoch RSI (14) | 26.88 | Neutral |
| CCI (20) | -132.87 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -6.39 | Sell |
| Bollinger %B (20,2) | 0.06 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.71 | Sell |
| Awesome (5,34) | -0.39 | Sell |
| Ultimate (7,14,28) | 22.94 | Buy |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 2.49 | Sell |
| ADX (14) | 17.81 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture tilts bearish. The RSI(14) is 40, and the stock trades below the SMA50 of $3.22, while the SMA200 sits at $13.37, suggesting longer-term headwinds despite any near-term moves.
Support is indicated at $2.49 and resistance at $3.59, framing a near-term barrier to gains. The 30-day price range spans from $1.86 to $3.34, highlighting the limited upside within the recent month and a wide potential downmove if momentum shifts.
Annualized volatility is high at 90%, underscoring substantial price variability and risk on a daily basis. Traders should watch for updates around the $2.49 level, where the current price aligns with the established support.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.49 | $2.49 | $3.29 | 0% | Neutral | |
| $2.13 | $2.84 | $4.08 | +14% | Neutral | |
| $1.79 | $2.50 | $3.80 | +1% | Neutral | |
| $1.72 | $2.51 | $3.98 | +1% | Neutral | |
| $1.61 | $2.44 | $4.00 | -2% | Neutral | |
| $1.30 | $2.05 | $3.46 | -18% | Bearish | |
| $1.81 | $2.93 | $5.10 | +18% | Neutral | |
| $2.09 | $3.50 | $6.23 | +41% | Bullish | |
| $1.83 | $3.15 | $5.73 | +26% | Bullish | |
| $1.86 | $3.29 | $6.12 | +32% | Bullish | |
| $2.26 | $4.59 | $9.29 | +84% | Bullish | |
| $2.52 | $5.60 | $12.79 | +125% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.49 | $2.49 | $2.97 | +0.00% |
| August 2026 | $2.08 | $2.50 | $3.11 | +0.37% |
| September 2026 | $2.17 | $2.64 | $3.35 | +5.63% |
| October 2026 | $2.12 | $2.60 | $3.34 | -1.62% |
| November 2026 | $1.99 | $2.47 | $3.21 | -5.05% |
| December 2026 | $2.01 | $2.50 | $3.29 | +1.44% |
Click any year to see its month-by-month BDRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BDRX price prediction for 2026 points to an average of $2.49 (low $2.49, high $3.29) — a potential gain of 0% on today's $2.49. A consolidation phase looks the most probable path here.
In 2027, BDRX is projected to trade between $2.13 and $4.08, averaging $2.84 — a potential gain of +14% from today's $2.49. That is up +14% on the projected 2026 average. Price action looks broadly range-bound.
Biodexa Pharmaceuticals Plc's 2028 outlook centres on $2.50, within a $1.79 to $3.80 range. That is -12% versus the projected 2027 average. That marks a +1% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, BDRX could reach as high as $3.98, with a base case around $2.51 and support toward $1.72 — roughly +1% from $2.49. Price action looks broadly range-bound.
Expect BDRX to range from $1.61 to $4.00 through 2030. The $2.44 average target implies a -2% move from current prices. That is -3% versus the projected 2029 average. A consolidation phase looks the most probable path here.
The BDRX price prediction for 2031 points to an average of $2.05 (low $1.30, high $3.46) — a potential decline of -18% on today's $2.49. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2032, BDRX is projected to trade between $1.81 and $5.10, averaging $2.93 — a potential gain of +18% from today's $2.49. That is up +43% on the projected 2031 average. A consolidation phase looks the most probable path here.
Biodexa Pharmaceuticals Plc's 2033 outlook centres on $3.50, within a $2.09 to $6.23 range. That is up +19% on the projected 2032 average. That marks a +41% change versus current levels. Momentum favours further upside here.
By 2034, BDRX could reach as high as $5.73, with a base case around $3.15 and support toward $1.83 — roughly +26% from $2.49. Buyers look set to stay in control over this stretch.
Expect BDRX to range from $1.86 to $6.12 through 2035. The $3.29 average target implies a +32% move from current prices. That is up +5% on the projected 2034 average. Momentum favours further upside here.
The BDRX price prediction for 2040 points to an average of $4.59 (low $2.26, high $9.29) — a potential gain of +84% on today's $2.49. Buyers look set to stay in control over this stretch.
In 2050, BDRX is projected to trade between $2.52 and $12.79, averaging $5.60 — a potential gain of +125% from today's $2.49. That is up +22% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in BDRX today (≈ 401.606426 BDRX) could be worth
$2,248.74
+$1,248.74 (+125%) by 2050 · US Dollar
Based on the average projected BDRX price of $5.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BDRXwould be worth at today's price.
$1,000 invested in BDRX on Jul 10, 2025 (≈ 22.47191 BDRX) would be worth
$55.96
-$944.04 (-94.4%) today · 0.06× · US Dollar
Based on a BDRX entry price of $44.5 vs. today's $2.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.94 | $846.94 | -15.3% |
| 1 month ago | $3.01 | $827.24 | -17.3% |
| 3 months ago | $3.36 | $741.07 | -25.9% |
| 6 months ago | $11.65 | $213.73 | -78.6% |
| 1 year ago | $44.5 | $55.96 | -94.4% |
| All time (5.0y) ago | $3,900,000 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BDRX forecast.
Our base-case forecast reaches $5.00 around 2050.
Implied market cap at $5.00: $4.52M
The year-by-year forecast shows a path from subdued performance to notable upside. In 2026 the average price is $2.49 with a 0% ROI, remaining neutral. By 2027 the average rises to $2.84 with a 14.2% ROI and still neutral sentiment.
In 2030 the average is $2.44 and the ROI is -2.1%, reflecting a downturn in that year. The year 2031 shows a more pronounced decline with an average of $2.05 and a -17.8% ROI, marked as bearish.
From 2032 onward, the forecast turns more positive: 2033 with an average of $3.50 and a 40.5% ROI (bullish), 2034 with $3.15 and 26.4% ROI (bullish), and 2035 with $3.29 and 32.3% ROI (bullish).
Longer horizons show strong upside: 2040 an average of $4.59 and 84.4% ROI (bullish), and 2050 an average of $5.60 with 124.9% ROI (bullish). These figures imply increasing upside potential but also ongoing volatility and risk, with uncertainty around earlier years and stronger visibility only in the later forecast.
Overall, the forward view suggests a transition from mixed to bullish sentiment in the mid-to-late 2030s and beyond, but investors should consider the likelihood of significant variability and the fact that these are estimates rather than guarantees.
Tap a question to reveal the answer.
Avg price $2.44; min $1.61; max $4.00; ROI -2.1%; sentiment NEUTRAL.
Forecasts show a mix of outcomes: some years neutral or bearish (e.g., 2031 with ROI -17.8%), and later years bullish (e.g., 2040 with ROI 84.4% and 2050 with ROI 124.9%). These are estimates, not guarantees, and reflect substantial year-to-year variability.
Yes, the max forecast for 2033 is $6.23, with other years showing potential highs such as 2034 $5.73 and 2035 $6.12; 2040 and 2050 also show higher maxs ($9.29 and $12.79 respectively).
Current price: $2.49. Market cap: $2.25M.
Bearish sentiment with RSI(14) at 40. 30-day range is $1.86–$3.34. Support is at $2.49 and resistance at $3.59. SMA50 is $3.22 and SMA200 is $13.37, indicating near-term headwinds.
Biodexa Pharmaceuticals Plc Community Discussion
0Share your Biodexa Pharmaceuticals Plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.